Skip to main content


Log in

Denosumab-related osteonecrosis of the jaws

  • Letter
  • Published:
Osteoporosis International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.


  1. Anastasilakis AD, Toulis KA, Polyzos SA, Terpos E (2009) RANKL inhibition for the management of patients with benign metabolic bone disorders. Expert Opin Investig Drugs 18:1085–1102

    Article  CAS  PubMed  Google Scholar 

  2. Kyrgidis A, Triaridis S, Vahtsevanos K, Antoniades K (2009) Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients. Expert Rev Anticancer Ther 9:1125–1134

    Article  CAS  PubMed  Google Scholar 

  3. Anastasilakis AD, Toulis KA, Goulis DG, Polyzos SA, Delaroudis S, Giomisi A, Terpos E (2009) Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res 41:721–729

    Article  CAS  PubMed  Google Scholar 

  4. Edwards BJ, Gounder M, McKoy JM, Boyd I, Farrugia M, Migliorati C, Marx R, Ruggiero S, Dimopoulos M, Raisch DW, Singhal S, Carson K, Obadina E, Trifilio S, West D, Mehta J, Bennett CL (2008) Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 9:1166–1172

    Article  PubMed  Google Scholar 

  5. Coleman RE (2008) Risks and benefits of bisphosphonates. Br J Cancer 98:1736–1740

    Article  CAS  PubMed  Google Scholar 

  6. Taylor KH, Middlefell LS, Mizen KD (2010) Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg Oct 15. doi:10.1016/j.bjoms.2009.08.030

  7. Henry D, von Moos R, Vadhan-Raj S, Hungria V, Spencer A, Hirsh V, Wang J, Jun S, Yeh H, Dansey R (2009) A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. European Journal of Cancer Supplements, Vol 7, Issue 3, Joint ECCO 15—34th ESMO Multidisciplinary Congress—Proffered Paper sessions 7(3):12

  8. Stopeck A, Body JJ, Fujiwara Y, Lipton A, Steger GG, Viniegra M, Fan M, Braun A, Dansey R, Jun S (2009) Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. European Journal of Cancer Supplements, Vol 7, Issue 3, Joint ECCO 15—34th ESMO Multidisciplinary Congress—Presidential session II 7(3):2–3

    Google Scholar 

  9. Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis C, Boukovinas I, Koloutsos G, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K (2009) Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356–5362

    Article  CAS  PubMed  Google Scholar 

  10. Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS (2008) Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med 121(475–483):e473

    Google Scholar 

  11. Kyrgidis A, Vahtsevanos K (2009) Osteonecrosis of the jaw in patients receiving oral bisphosphonates. Osteoporos Int. doi:10.1007/s00198-009-01089-5

    PubMed  Google Scholar 

  12. Kyrgidis A, Vahtsevanos K (2009) "Fatigue" having a role in the pathogenesis of osteonecrosis of the jaws. Clin Oral Investig 13:479–480

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest


Author information

Authors and Affiliations


Corresponding author

Correspondence to A. Kyrgidis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kyrgidis, A., Toulis, K.A. Denosumab-related osteonecrosis of the jaws. Osteoporos Int 22, 369–370 (2011).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: